Abdelnabi R, Foo CS, Kaptein SJF, et al. 2021. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. eBioMedicine 72: 103595.
Aid M, Sciacca M, McMahan K, et al. 2023. Mpox infection protects against re-challenge in rhesus macaques. Cell 186: 4652-4661.e4613.
Allan-Blitz LT, Gandhi M, Adamson P, Park I, Bolan G, Klausner JD. 2023. A Position Statement on Mpox as a Sexually Transmitted Disease. Clinical Infectious Diseases 76: 1508-1512.
Ao D, Lan T, He X, et al. 2022. SARS-CoV-2 Omicron variant: Immune escape and vaccine development. MedComm 3: e126.
Araf Y, Nipa JF, Naher S, et al. 2024. Insights into the Transmission, Host Range, Genomics, Vaccination, and Current Epidemiology of the Monkeypox Virus. Veterinary Medicine International 2024: 8839830.
Baek SH, Oh H, Koo BS, et al. 2022. Cynomolgus Macaque Model for COVID-19 Delta Variant. Immune Network 22: e48.
Bakowski MA, Beutler N, Wolff KC, et al. 2021. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nature Communications 12: 3309.
Bambery B, Selgelid M, Weijer C, Savulescu J, Pollard AJ. 2016. Ethical Criteria for Human Challenge Studies in Infectious Diseases. Public Health Ethics 9: 92-103.
Bao L, Deng W, Huang B, et al. 2020. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583: 830-833.
Barnewall RE, Fisher DA, Robertson AB, Vales PA, Knostman KA, Bigger JE. 2012. Inhalational monkeypox virus infection in cynomolgus macaques. Frontiers in Cellular and Infection Microbiology 2: 117.
Baum A, Ajithdoss D, Copin R, et al. 2020. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370: 1110-1115.
Bixler SL, Stefan CP, Jay AN, et al. 2022. Exposure Route Influences Disease Severity in the COVID-19 Cynomolgus Macaque Model. Viruses 14.
Bodewes R, Rimmelzwaan GF, Osterhaus AD. 2010. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Review of Vaccines 9: 59-72.
Bosaeed M, Alharbi A, Mahmoud E, et al. 2022. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clinical Microbiology and Infection 28: 602-608.
Brown E, Ozawa K, Moccetti F, et al. 2021. Arterial Platelet Adhesion in Atherosclerosis‐Prone Arteries of Obese, Insulin‐Resistant Nonhuman Primates. Journal of the American Heart Association 10: e019413.
Brown JN, Estep RD, Lopez-Ferrer D, et al. 2010. Characterization of macaque pulmonary fluid proteome during monkeypox infection: dynamics of host response. Molecular & Cellular Proteomics 9: 2760-2771.
Buchman GW, Cohen ME, Xiao Y, et al. 2010. A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine 28: 6627-6636.
Bushmaker T, Feldmann F, Lovaglio J, et al. 2023. Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques. The Journal of Infectious Diseases 228: S721-s729.
Carlsson HE, Schapiro SJ, Farah I, Hau J. 2004. Use of primates in research: a global overview. American Journal of Primatology 63: 225-237.
Chahroudi A, Bosinger SE, Vanderford TH, Paiardini M, Silvestri G. 2012. Natural SIV hosts: showing AIDS the door. Science 335: 1188-1193.
Chandrashekar A, Liu J, Martinot AJ, et al. 2020. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369: 812-817.
Chandrashekar A, Liu J, Yu J, et al. 2021. Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. Science Translational Medicine 13: eabj2641.
Chen L, He Y, Liu H, Shang Y, Guo G. 2024. Potential immune evasion of the severe acute respiratory syndrome coronavirus 2 Omicron variants. Frontiers in Immunology 15: 1339660.
Chen N, Li G, Liszewski MK, et al. 2005. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 340: 46-63.
Cockrell AS, Johnson JC, Moore IN, et al. 2018. A spike-modified Middle East respiratory syndrome coronavirus (MERS-CoV) infectious clone elicits mild respiratory disease in infected rhesus macaques. Scientific Reports 8: 10727.
Corbett KS, Flynn B, Foulds KE, et al. 2020. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine 383: 1544-1555.
Corbett KS, Werner AP, Connell SO, et al. 2021. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nature Immunology 22: 1306-1315.
Daniel MD, Letvin NL, King NW, et al. 1985. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 228: 1201-1204.
de Wit E, Feldmann F, Cronin J, et al. 2020. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Science USA 117: 6771-6776.
de Wit E, Fouchier RA. 2008. Emerging influenza. Journal of Clinical Virology 41: 1-6.
Deng W, Bao L, Gao H, et al. 2020. Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques. Nature Communications 11: 4400.
Denzler KL, Babas T, Rippeon A, et al. 2011. Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques. Vaccine 29: 9684-9690.
Driouich J-S, Cochin M, Lingas G, et al. 2021. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nature Communications 12: 1735.
Ebeling M, Küng E, See A, et al. 2011. Genome-based analysis of the nonhuman primate Macaca fascicularis as a model for drug safety assessment. Genome Research 21: 1746-1756.
Fenwick C, Turelli P, Duhoo Y, et al. 2023. Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys. Journal of Infection 87: 524-537.
Fenwick C, Turelli P, Ni D, et al. 2022. Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys. Nature Microbiology 7: 1376-1389.
Fischer RJ, Bushmaker T, Williamson BN, et al. 2024. Compartmentalized SARS-CoV-2 Replication in the Upper vs Lower Respiratory Tract After Intranasal Inoculation or Aerosol Exposure. The Journal of Infectious Diseases 230: 657-661.
Gagne M, Flynn BJ, Andrew SF, et al. 2024. Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates. Nature Immunology 25: 1913-1927.
Gagne M, Moliva JI, Foulds KE, et al. 2022. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell 185: 1556-1571.e1518.
Gao Q, Bao L, Mao H, et al. 2020. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369: 77-81.
Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. 2002. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerging Infectious Diseases 8: 503-507.
Gibbs RA, Rogers J, Katze MG, et al. 2007. Evolutionary and Biomedical Insights from the Rhesus Macaque Genome. Science 316: 222-234.
Girometti N, Byrne R, Bracchi M, et al. 2022. Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. The Lancet Infectious Diseases 22: 1321-1328.
Goff A, Mucker E, Raymond J, Fisher R, Bray M, Hensley L, Paragas J. 2011a. Infection of cynomolgus macaques with a recombinant monkeypox virus encoding green fluorescent protein. Archives of Virology 156: 1877-1881.
Goff AJ, Chapman J, Foster C, et al. 2011b. A novel respiratory model of infection with monkeypox virus in cynomolgus macaques. Journal of Virology 85: 4898-4909.
Grant RJ, Baldwin CD, Nalca A, et al. 2010. Application of the Ibis-T5000 pan-Orthopoxvirus assay to quantitatively detect monkeypox viral loads in clinical specimens from macaques experimentally infected with aerosolized monkeypox virus. The American Journal of Tropical Medicine and Hygiene 82: 318-323.
Han Y, Duan X, Yang L, et al. 2021. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature 589: 270-275.
Hartman AL, Nambulli S, McMillen CM, et al. 2020. SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and shedding of infectious virus from both respiratory and gastrointestinal tracts. PLoS Pathogens 16: e1008903.
Hatch GJ, Graham VA, Bewley KR, et al. 2013. Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. Journal of Virology 87: 7805-7815.
Hazra A, Zucker J, Bell E, et al. 2024. Mpox in people with past infection or a complete vaccination course: a global case series. The Lancet Infectious Diseases 24: 57-64.
Herate C, Ferrier-Rembert A, Relouzat F, et al. 2025. Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model. Nature Communications 16: 7306.
Hérate C, Marlin R, Touret F, et al. 2023. Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model. Heliyon 9: e16664.
Heraud JM, Edghill-Smith Y, Ayala V, et al. 2006. Subunit recombinant vaccine protects against monkeypox. The Journal of Immunology 177: 2552-2564.
Hermet P, Delache B, Herate C, et al. 2023. Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates. PLoS Pathogens 19: e1011532.
Hirao LA, Draghia-Akli R, Prigge JT, et al. 2011. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. The Journal of Infectious Diseases 203: 95-102.
Hoang TN, Pino M, Boddapati AK, et al. 2021. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell 184: 460-475.e421.
Hooper JW, Thompson E, Wilhelmsen C, et al. 2004. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. Journal of Virology 78: 4433-4443.
Huang Y, Mu L, Wang W. 2022. Monkeypox: epidemiology, pathogenesis, treatment and prevention. Signal Transduction and Targeted Therapy 7: 373.
Huggins J, Goff A, Hensley L, et al. 2009. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrobial Agents and Chemotherapy 53: 2620-2625.
Iizuka I, Ami Y, Suzaki Y, et al. 2017. A Single Vaccination of Nonhuman Primates with Highly Attenuated Smallpox Vaccine, LC16m8, Provides Long-term Protection against Monkeypox. Japanese Journal of Infectious Diseases 70: 408-415.
Ireland RE, Davies CD, Keyser E, et al. 2022. Histopathological and Immunological Findings in the Common Marmoset Following Exposure to Aerosolized SARS-CoV-2. Viruses 14.
Jacob-Dolan C, Feldman J, McMahan K, et al. 2021. Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection. Journal of Virology 95.
Jacob-Dolan C, Ty D, Hope D, et al. 2024. Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques. Science Translational Medicine 16: eadl4317.
Jang WD, Jeon S, Kim S, Lee SY. 2021. Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. Proceedings of the National Academy of Sciences USA 118: e2024302118.
Johnson RF, Dyall J, Ragland DR, et al. 2011. Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route. Journal of Virology 85: 2112-2125.
Jones BE, Brown-Augsburger PL, Corbett KS, et al. 2021. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Science Translational Medicine 13.
Jones SM, Feldmann H, Ströher U, et al. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature Medicine 11: 786-790.
Kaptein SJF, Jacobs S, Langendries L, et al. 2020. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity. Proceedings of the National Academy of Sciences USA 117: 26955-26965.
Khandia R, Singhal S, Alqahtani T, et al. 2022. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environmental Research 209: 112816.
Krug C, Tarantola A, Chazelle E, et al. 2023. Mpox outbreak in France: epidemiological characteristics and sexual behaviour of cases aged 15 years or older, 2022. Eurosurveillance 28: 2200923
Kwon T. 2024. Utilizing non-human primate models to combat recent COVID-19/SARS-CoV-2 and viral infectious disease outbreaks. Journal of Medical Primatology 53: e12689.
Lamers MM, Beumer J, van der Vaart J, et al. 2020. SARS-CoV-2 productively infects human gut enterocytes. Science 369: 50-54.
Li Q, Chen Y, Zhang W, et al. 2024. Mpox virus Clade IIb infected Cynomolgus macaques via mimic natural infection routes closely resembled human mpox infection. Emerging Microbes and Infections 13: 2332669.
Lu S, Zhao Y, Yu W, et al. 2020. Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduction and Targeted Therapy 5: 157.
Maisonnasse P, Aldon Y, Marc A, et al. 2021. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Nature Communications 12: 6097.
Maisonnasse P, Guedj J, Contreras V, et al. 2020. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature 585: 584-587.
Marlin R, Desjardins D, Contreras V, et al. 2022. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates. Nature Communications 13: 5108.
McMahon CL, Staples H, Gazi M, Carrion R, Hsieh J. 2021. SARS-CoV-2 targets glial cells in human cortical organoids. Stem Cell Reports 16: 1156-1164.
Melton A, Doyle-Meyers LA, Blair RV, et al. 2021. The pigtail macaque (Macaca nemestrina) model of COVID-19 reproduces diverse clinical outcomes and reveals new and complex signatures of disease. PLoS Pathogens 17: e1010162.
Mitjà O, Ogoina D, Titanji BK, Galvan C, Muyembe JJ, Marks M, Orkin CM. 2023. Monkeypox. Lancet 401: 60-74.
Monteil V, Kwon H, Prado P, et al. 2020. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell 181: 905-913.e907.
Mucker EM, Freyn AW, Bixler SL, et al. 2024. Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates. Cell 187: 5540-5553.e5510.
Mukhopadhyay L, Yadav PD, Gupta N, et al. 2021. Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates. Indian Journal of Medical Research 153: 93-114.
Munster VJ, Feldmann F, Williamson BN, et al. 2020. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature 585: 268-272.
Musumeci S, Laflamme J, Kaiser L, Segeral O, Calmy A. 2023. Characteristics of possible mpox reinfection cases: literature review. Journal of Travel Medicine 30.
Naga NG, Nawar EA, Mobarak AA, Faramawy AG, Al-Kordy HMH. 2025. Monkeypox: a re-emergent virus with global health implications - a comprehensive review. Tropical Diseases, Travel Medicine and Vaccines 11: 2.
Nalca A, Livingston VA, Garza NL, Zumbrun EE, Frick OM, Chapman JL, Hartings JM. 2010. Experimental infection of cynomolgus macaques (Macaca fascicularis) with aerosolized monkeypox virus. PLoS One 5.
National Academies of Sciences E, and Medicine. 2023. Nonhuman Primate Models in Biomedical Research: State of the Science and Future Needs. Washington, DC, The National Academies Press.
Nomura T, Yamamoto H, Nishizawa M, et al. 2021. Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques. PLoS Pathogens 17: e1009668.
Noyce RS, Westfall LW, Fogarty S, et al. 2023. Single Dose of Recombinant Chimeric Horsepox Virus (TNX-801) Vaccination Protects Macaques from Lethal Monkeypox Challenge. Viruses 15.
Pan H, Peto R, Henao-Restrepo AM, et al. 2021. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. New England Journal of Medicine 384: 497-511.
Parsons MS, Bolton DL. 2025. The utility of nonhuman primate models for understanding acute HIV-1 infection. Current Opinion in HIV and AIDS 20: 218-227.
Pascal KE, Dudgeon D, Trefry JC, et al. 2018. Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. The Journal of Infectious Diseases 218: S612-s626.
Pavot V, Berry C, Kishko M, et al. 2023. Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates. Nature Communications 14: 1309.
Peña JC, Ho WZ. 2017. Non-Human Primate Models of Tuberculosis. Tuberculosis and the Tubercle Bacillus 163-176.
Pinto MV, Merkel TJ. 2017. Pertussis disease and transmission and host responses: insights from the baboon model of pertussis. Journal of Infection 74 Suppl 1: S114-s119.
Pizzorno A, Padey B, Dubois J, et al. 2020. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Research 181: 104878.
Planas D, Saunders N, Maes P, et al. 2022. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602: 671-675.
Polozov AI, Sobolevskiĭ VI, Vorob'ev AA, Patrikeev GT, Zelenskiĭ LI. 1978. Use of the monkey pox virus for evaluating the intensity of the immunity against smallpox in experiments on M. rhesus. Voprosy Virusologii 2: 215-220.
Rockx B, Kuiken T, Herfst S, et al. 2020. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368: 1012-1015.
Routhu NK, Gangadhara S, Lai L, et al. 2022. A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. Science Immunology 7: eabo0226.
Routhu NK, Stampfer SD, Lai L, et al. 2023. Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates. Science Immunology 8: eadg7015.
Russo AT, Berhanu A, Bigger CB, Prigge J, Silvera PM, Grosenbach DW, Hruby D. 2020. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine 38: 644-654.
Russo AT, Grosenbach DW, Brasel TL, et al. 2018. Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques. The Journal of Infectious Diseases 218: 1490-1499.
Sah R, Abdelaal A, Reda A, et al. 2022. Monkeypox and Its Possible Sexual Transmission: Where Are We Now with Its Evidence? Pathogens 11.
Saijo M, Ami Y, Suzaki Y, et al. 2009. Virulence and pathophysiology of the Congo Basin and West African strains of monkeypox virus in non-human primates. Journal of General Virology 90: 2266-2271.
Sano E, Suzuki T, Hashimoto R, et al. 2022. Cell response analysis in SARS-CoV-2 infected bronchial organoids. Communications Biology 5: 516.
Sato A, Tsukiyama T, Komeno M, et al. 2023. Generation of a familial hypercholesterolemia model in non-human primate. Scientific Reports 13: 15649.
Schweitzer L, Bachelard N. 2023. Alternative methods to animal testing: the need for funding and dissemination. Biologie Aujourdhui 217: 183-191.
Shaan Lakshmanappa Y, Elizaldi SR, Roh JW, et al. 2021. SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. Nature Communications 12: 541.
Shan C, Yao Y-F, Yang X-L, et al. 2020. Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques. Cell Research 30: 670-677.
Sharma M, Nag M, Del Prete GQ. 2024. Minimally Modified HIV-1 Infection of Macaques: Development, Utility, and Limitations of Current Models. Viruses 16.
Si L, Bai H, Rodas M, et al. 2021. A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nature Biomedical Engineering 5: 815-829.
Simonis A, Theobald SJ, Fätkenheuer G, Rybniker J, Malin JJ. 2021. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Molecular Medicine 13: e13105.
Singh DK, Singh B, Ganatra SR, et al. 2021a. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nature Microbiology 6: 73-86.
Singh S, McNab C, Olson RM, et al. 2021b. How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic. Lancet 398: 2109-2124.
Song H, Josleyn N, Janosko K, et al. 2013. Monkeypox virus infection of rhesus macaques induces massive expansion of natural killer cells but suppresses natural killer cell functions. PLoS One 8: e77804.
St Claire MC, Ragland DR, Bollinger L, Jahrling PB. 2017. Animal Models of Ebolavirus Infection. Comparative Medicine 67: 253-262.
Stittelaar KJ, van Amerongen G, Kondova I, et al. 2005. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. Journal of Virology 79: 7845-7851.
Sutton TC, Subbarao K. 2015. Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus. Virology 479-480: 247-258.
Thornhill JP, Antinori A, Orkin CM. 2022. Monkeypox Virus Infection across 16 Countries - April-June 2022. Reply. New England Journal of Medicine 387: e69.
Tree JA, Hall G, Pearson G, et al. 2015. Sequence of pathogenic events in cynomolgus macaques infected with aerosolized monkeypox virus. Journal of Virology 89: 4335-4344.
Umar SK, Diggle MA. 2025. The Ebola virus - going beyond the bleeding edge. Journal of Medical Microbiology 74: 001998.
van Doremalen N, Lambe T, Spencer A, et al. 2020. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586: 578-582.
van Doremalen N, Singh M, Saturday TA, et al. 2022. SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta. bioRxiv.
VanBlargan LA, Errico JM, Halfmann PJ, et al. 2022. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nature Medicine 28: 490-495.
Via LE, England K, Weiner DM, et al. 2015. A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets. Antimicrobial Agents of Chemotherapy 59: 4181-4189.
Vogel AB, Kanevsky I, Che Y, et al. 2021. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592: 283-289.
von Magnus P, Andersen EK, Petersen KB, Birch Andersen A. 1959. A pox-like disease in cynomolgus monkeys. Acta Pathologica et Microbiologica Scandinavica 46: 156-176.
Wen L, Tang K, Chik KK, et al. 2021. In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor. International Journal of Biological Sciences 17: 1555-1564.
Williamson BN, Feldmann F, Schwarz B, et al. 2020. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 585: 273-276.
Wiseman RW, Karl JA, Bohn PS, Nimityongskul FA, Starrett GJ, O'Connor DH. 2013. Haplessly hoping: macaque major histocompatibility complex made easy. Ilar Journal 54: 196-210.
Woolsey C, Borisevich V, Prasad AN, et al. 2021. Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nature Immunology 22: 86-98.
Ye Q, Zhang D, Zhang RR, et al. 2024. A penta-component mpox mRNA vaccine induces protective immunity in nonhuman primates. Nature Communications 15: 10611.
Yu J, Tostanoski LH, Peter L, et al. 2020a. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369: 806-811.
Yu P, Qi F, Xu Y, et al. 2020b. Age-related rhesus macaque models of COVID-19. Animal Models and Experimental Medicine 3: 93-97.
Yu W, Wang J, Yang Y, et al. 2023. SARS-CoV-2 Omicron (B.1.1.529) infection in rhesus macaques, hamsters, and BALB/c mice with severe lung histopathological damage. Journal of Medical Virology 95: e28846.
Yuan Z, Pavel MA, Wang H, et al. 2022. Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture. Communications Biology 5: 958.
Zabaleta N, Bhatt U, Hérate C, et al. 2022. Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. Molecular Therapy 30: 2952-2967.
Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L. 2001. The Pathology of Experimental Aerosolized Monkeypox Virus Infection in Cynomolgus Monkeys (Macaca fascicularis). Laboratory Investigation 81: 1581-1600.
Zhu L, Pan S, Huang B, et al. 2025. Tiantan vaccinia virus-based vaccine with promising safety provides sustained protection against mpox in non-human primates. Nature Communications 16: 7183.
Zost SJ, Gilchuk P, Case JB, et al. 2020. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584: 443-449.
Zuiani A, Dulberger CL, De Silva NS, et al. 2024. A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell 187: 1363-1373.e1312.













